Skip to content

Benefit of Ethanol Sclerotherapy of Endometriomas Before Ovarian Stimulation on Pregnancy Rates in IVF/ICSI

Benefit of Ethanol Sclerotherapy of Endometriomas Before Ovarian Stimulation on Pregnancy Rates in IVF/ICSI

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06878053
Acronym
SCLERENDO
Enrollment
174
Registered
2025-03-14
Start date
2025-06-01
Completion date
2029-06-01
Last updated
2025-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertile Women Undergoing IVF or ICSI

Brief summary

Evaluation of progressive pregnancy rates (with an embryo with cardiac activity at 12 weeks), on a first attempt at IVF/ICSI (fresh and frozen embryo transfers) following the discovery of one or two endometrioma(s) of 30 to 80 mm, without a history of cystectomy, and comparison between the two groups: ethanol sclerotherapy and therapeutic abstention

Interventions

The originality of this project consists in evaluating the effectiveness of ethanol sclerotherapy of endometrioma(s) in infertile patients before IVF/ICSI, excluding patients who have previously had an ovarian cystectomy. To date, no prospective randomized comparative study between ethanol sclerotherapy of endometriomas and therapeutic abstention has been carried out.

Sponsors

Poissy-Saint Germain Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No

Inclusion criteria

* Infertile women aged 18 to 43, * Presenting one or 2 endometriotic cysts of 30 mm to 80 mm long axis, confirmed by ultrasound and/or pelvic MRI and without signs of atypia, * With indication of IVF/ICSI, first IVF/ICSI after the discovery of endometriosis cyst(s), * Having given their consent.

Exclusion criteria

* A history of ovarian cystectomy, * A non-homogeneous cyst that cannot be punctured (risk of incomplete aspiration), * Complex adnexal image that cannot exclude an associated hematosalpinx (communicating hematosalpinx, tissue component), * A recent tubo-ovarian infection, * An active, untreated vaginal infection, * Anticoagulant treatment at a therapeutic dose, * All adult patients protected by law (under guardianship or curatorship), * Problems understanding the French language, * Participation in intervention research, * All patients not affiliated to the social security system.

Design outcomes

Primary

MeasureTime frameDescription
cumulative rate of active pregnancies12 weeksCumulative rate of active pregnancies defined by the presence of an embryo with cardiac activity at 12 weeks per IVF/ICSI cycle, including fresh and frozen embryo transfers in an IVF/ICSI attempt.

Contacts

Primary ContactNelly SWIERKOWSKI-BLANCHARD, MD
nelly.swierkowskiblanchard@ght-yvelinesnord.fr+33139275259

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026